Thrombin Pathway in 'Trial of PeriOperative Endocrine Therapy Individualising Care' [SUBSTUDY OF 700029612]

Trial Profile

Thrombin Pathway in 'Trial of PeriOperative Endocrine Therapy Individualising Care' [SUBSTUDY OF 700029612]

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Anastrozole (Primary) ; Letrozole (Primary) ; Antineoplastics
  • Indications Early breast cancer
  • Focus Pharmacodynamics
  • Acronyms T-POETIC-v1
  • Most Recent Events

    • 13 Dec 2013 Accrual to date is 87% according to United Kingdom Clinical Research Network.
    • 14 Nov 2013 Planned end date changed from 31 Oct 2013 to 31 Dec 2013 as reported by United Kingdom Clinical Research Network record.
    • 13 Nov 2013 Accrual to date is 82% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top